Literature DB >> 27806237

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Masanori Wakisaka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27806237     DOI： 10.1056/NEJMc1611290

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.

Authors:  Zengguang Kuang; Ningning Hou; Chengxia Kan; Fang Han; Hongyan Qiu; Xiaodong Sun
Journal:  Int Urol Nephrol       Date:  2022-08-29       Impact factor: 2.266

Review 2.  Ion channels and transporters in diabetic kidney disease.

Authors:  Denisha Spires; Anna D Manis; Alexander Staruschenko
Journal:  Curr Top Membr       Date:  2019-02-18       Impact factor: 3.049

3.  Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials.

Authors:  Kaberi Dasgupta; Ruth Sapir-Pichhadze; Nadia Khan
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-12-18       Impact factor: 3.738

4.  Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.

Authors:  Ling Qu; Xiaochun Liang; Guoqing Tian; Gaili Zhang; Qunli Wu; Xiumei Huang; Yazhong Cui; Yuling Liu; Zhufang Shen; Changqing Xiao; Yingfen Qin; Heng Miao; Yongyan Zhang; Ziling Li; Shandong Ye; Xuezhi Zhang; Jing Yang; Guiwen Cao; Yi Li; Gangyi Yang; Ji Hu; Xiaoyue Wang; Zhengfang Li; Yukun Li; Xiuzhen Zhang; Guangde Zhang; Li Chen; Wenjin Hua; Ming Yu; Chunyan Lu; Xiaomei Zhang; Hong Jiang
Journal:  Diabetes Care       Date:  2021-04-08       Impact factor: 17.152

Review 5.  Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy.

Authors:  Janaina Paulini; Eliza Higuti; Rosana M C Bastos; Samirah A Gomes; Érika B Rangel
Journal:  Stem Cells Int       Date:  2016-12-13       Impact factor: 5.443

6.  Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).

Authors:  Guntram Schernthaner; Kamlesh Khunti; Chaim Lotan; Michel Burnier; Heinz Drexel; Martin Prázný
Journal:  Ther Clin Risk Manag       Date:  2017-12-13       Impact factor: 2.423

Review 7.  A more tubulocentric view of diabetic kidney disease.

Authors:  Letizia Zeni; Anthony G W Norden; Giovanni Cancarini; Robert J Unwin
Journal:  J Nephrol       Date:  2017-08-24       Impact factor: 3.902

8.  Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy.

Authors:  Masarori Wakisaka; Tetsuhiko Nagao
Journal:  Glycobiology       Date:  2017-08-01       Impact factor: 4.313

9.  Recovery from Diabetic Macular Edema in a Diabetic Patient After Minimal Dose of a Sodium Glucose Co-Transporter 2 Inhibitor.

Authors:  Hideyuki Yoshizumi; Tetsushi Ejima; Tetsuhiko Nagao; Masanori Wakisaka
Journal:  Am J Case Rep       Date:  2018-04-19

Review 10.  Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease.

Authors:  Masanori Wakisaka; Kuniyuki Nakamura; Toshiaki Nakano; Takanari Kitazono
Journal:  J Endocr Soc       Date:  2021-05-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.